Literature DB >> 35655816

Cut-off values for low skeletal muscle mass at the level of the third cervical vertebra (C3) in patients with head and neck cancer.

Najiba Chargi1, Sandra I Bril1, Ernst J Smid2, Pim A de Jong3, Remco de Bree1.   

Abstract

Background: Low skeletal muscle mass is associated with adverse outcomes in patients with cancer. For patients with head and neck cancer (HNC), skeletal muscle mass is often assessed at the third cervical vertebra on head and neck imaging. Due to the unavailability of standardized cut-off values for low skeletal muscle mass in patients with head and cancer, there is heterogeneousness of cut-off values for low skeletal muscle mass described in literature. Therefore, we aim to provide standardized cut-off values for low skeletal muscle mass in HNC patients.
Methods: A retrospective cohort study was performed. Between 2008 and 2018, HNC patients with head and neck imaging were included. Skeletal muscle area (SMA) was manually delineated at the level of the third cervical vertebra and corrected for patients squared height to obtain the cervical skeletal muscle mass index. Gender and body-mass index specific cut-off values for low skeletal muscle mass were calculated based on mean cervical skeletal muscle mass index minus 2 standard deviations as suggested in literature.
Results: Of the 1,415 included patients, the majority was male (69.8%) and had a body mass index below 25 kg/m2 (59.2%). A primary tumor localization in the oropharynx (35.3%) and a tumor, node, metastasis stage IV tumor (60.5%) were most frequently observed. Cervical skeletal muscle mass index was significantly correlated with gender (r2=0.4, P<0.01) and body mass index (r2=0.4, P<0.01). For male patients with a body mass index <25 and ≥25 kg/m2, a cervical skeletal muscle mass index of respectively ≤6.8 and ≤8.5 cm2/m2 was defined for low skeletal muscle mass. For female patients with a body mass index <25 and ≥25 kg/m2, a cervical skeletal muscle mass index of respectively ≤5.3 and ≤6.4 cm2/m2 was defined for low skeletal muscle mass. Conclusions: This study is the first to provide standardized cut-off values for low skeletal muscle mass at the level of the third cervical vertebra in patients with HNC. This information may aid in the uniformity of low skeletal muscle mass definition in research. 2022 Quantitative Imaging in Medicine and Surgery. All rights reserved.

Entities:  

Keywords:  Skeletal muscle mass; cut-off values; head and neck cancer (HNC); imaging biomarker; sarcopenia

Year:  2022        PMID: 35655816      PMCID: PMC9131345          DOI: 10.21037/qims-21-911

Source DB:  PubMed          Journal:  Quant Imaging Med Surg        ISSN: 2223-4306


  32 in total

Review 1.  Assessment of body composition and sarcopenia in patients with esophageal cancer: a systematic review and meta-analysis.

Authors:  P R Boshier; R Heneghan; S R Markar; V E Baracos; D E Low
Journal:  Dis Esophagus       Date:  2018-08-01       Impact factor: 3.429

2.  Low skeletal muscle mass is a strong predictive factor for surgical complications and a prognostic factor in oral cancer patients undergoing mandibular reconstruction with a free fibula flap.

Authors:  E Ansari; N Chargi; J T M van Gemert; R J J van Es; F J Dieleman; A J W P Rosenberg; E M Van Cann; R de Bree
Journal:  Oral Oncol       Date:  2019-12-25       Impact factor: 5.337

3.  A multicompartment body composition technique based on computerized tomography.

Authors:  B Chowdhury; L Sjöström; M Alpsten; J Kostanty; H Kvist; R Löfgren
Journal:  Int J Obes Relat Metab Disord       Date:  1994-04

4.  Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index.

Authors:  Lisa Martin; Laura Birdsell; Neil Macdonald; Tony Reiman; M Thomas Clandinin; Linda J McCargar; Rachel Murphy; Sunita Ghosh; Michael B Sawyer; Vickie E Baracos
Journal:  J Clin Oncol       Date:  2013-03-25       Impact factor: 44.544

5.  Radiologically Defined Sarcopenia Affects Survival in Head and Neck Cancer: A Meta-Analysis.

Authors:  Amanda Wong; Daniel Zhu; Dennis Kraus; Tristan Tham
Journal:  Laryngoscope       Date:  2020-03-27       Impact factor: 3.325

6.  Sarcopenia with inflammation as a predictor of survival in patients with head and neck cancer.

Authors:  Kohei Yamahara; Akifumi Mizukoshi; Kana Lee; Satoshi Ikegami
Journal:  Auris Nasus Larynx       Date:  2021-04-18       Impact factor: 1.863

7.  The association of pretreatment low skeletal muscle mass with chemotherapy dose-limiting toxicity in patients with head and neck cancer undergoing primary chemoradiotherapy with high-dose cisplatin.

Authors:  Sandra I Bril; Abrahim Al-Mamgani; Najiba Chargi; Peter Remeijer; Lot A Devriese; Jan Paul de Boer; Remco de Bree
Journal:  Head Neck       Date:  2021-10-29       Impact factor: 3.821

8.  A comparative study of software programmes for cross-sectional skeletal muscle and adipose tissue measurements on abdominal computed tomography scans of rectal cancer patients.

Authors:  Jeroen L A van Vugt; Stef Levolger; Arvind Gharbharan; Marcel Koek; Wiro J Niessen; Jacobus W A Burger; Sten P Willemsen; Ron W F de Bruin; Jan N M IJzermans
Journal:  J Cachexia Sarcopenia Muscle       Date:  2016-11-22       Impact factor: 12.910

9.  Patterns, Predictors, and Prognostic Value of Skeletal Muscle Mass Loss in Patients with Locally Advanced Head and Neck Cancer Undergoing Cisplatin-Based Chemoradiotherapy.

Authors:  Najiba Chargi; Inge Wegner; Navid Markazi; Ernst Smid; Pim de Jong; Lot Devriese; Remco de Bree
Journal:  J Clin Med       Date:  2021-04-18       Impact factor: 4.241

10.  Prognostic impact of sarcopenia in patients with head and neck cancer treated with surgery or radiation: A meta-analysis.

Authors:  Yukinori Takenaka; Norihiko Takemoto; Ryohei Oya; Hidenori Inohara
Journal:  PLoS One       Date:  2021-10-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.